CN109069493A - 用氘代jak抑制剂治疗脱毛障碍 - Google Patents

用氘代jak抑制剂治疗脱毛障碍 Download PDF

Info

Publication number
CN109069493A
CN109069493A CN201780027427.2A CN201780027427A CN109069493A CN 109069493 A CN109069493 A CN 109069493A CN 201780027427 A CN201780027427 A CN 201780027427A CN 109069493 A CN109069493 A CN 109069493A
Authority
CN
China
Prior art keywords
compound
days
pharmaceutically acceptable
acceptable salt
phosphate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780027427.2A
Other languages
English (en)
Chinese (zh)
Inventor
A·T·瓦格纳
J·V·卡塞拉
P·B·格雷汉姆
V·布拉曼
V·尤塔姆辛格
J·冯赫恩
C·E·汉密尔顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharmaceutical Industry Co ltd
Original Assignee
Concert Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60203616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN109069493(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc
Priority to CN202610039132.8A priority Critical patent/CN121868312A/zh
Publication of CN109069493A publication Critical patent/CN109069493A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780027427.2A 2016-05-04 2017-05-04 用氘代jak抑制剂治疗脱毛障碍 Pending CN109069493A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202610039132.8A CN121868312A (zh) 2016-05-04 2017-05-04 用氘代jak抑制剂治疗脱毛障碍

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201662331827P 2016-05-04 2016-05-04
US62/331,827 2016-05-04
US201662338869P 2016-05-19 2016-05-19
US62/338,869 2016-05-19
US201662418774P 2016-11-07 2016-11-07
US62/418,774 2016-11-07
US201662419237P 2016-11-08 2016-11-08
US62/419,237 2016-11-08
US201662434404P 2016-12-14 2016-12-14
US62/434,404 2016-12-14
US201762466358P 2017-03-02 2017-03-02
US62/466,358 2017-03-02
US201762492758P 2017-05-01 2017-05-01
US62/492,758 2017-05-01
PCT/US2017/031142 WO2017192905A1 (en) 2016-05-04 2017-05-04 Treatment of hair loss disorders with deuterated jak inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202610039132.8A Division CN121868312A (zh) 2016-05-04 2017-05-04 用氘代jak抑制剂治疗脱毛障碍

Publications (1)

Publication Number Publication Date
CN109069493A true CN109069493A (zh) 2018-12-21

Family

ID=60203616

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780027427.2A Pending CN109069493A (zh) 2016-05-04 2017-05-04 用氘代jak抑制剂治疗脱毛障碍
CN202610039132.8A Pending CN121868312A (zh) 2016-05-04 2017-05-04 用氘代jak抑制剂治疗脱毛障碍

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202610039132.8A Pending CN121868312A (zh) 2016-05-04 2017-05-04 用氘代jak抑制剂治疗脱毛障碍

Country Status (21)

Country Link
US (3) US10561659B2 (https=)
EP (2) EP3452039B1 (https=)
JP (3) JP7145080B2 (https=)
KR (3) KR20190003711A (https=)
CN (2) CN109069493A (https=)
AU (3) AU2017261286B2 (https=)
BR (1) BR112018072339A2 (https=)
CA (1) CA3022519A1 (https=)
DK (1) DK3452039T3 (https=)
ES (1) ES2988629T3 (https=)
FI (1) FI3452039T3 (https=)
HR (1) HRP20241345T1 (https=)
HU (1) HUE068643T2 (https=)
LT (1) LT3452039T (https=)
MX (6) MX388054B (https=)
PL (1) PL3452039T3 (https=)
PT (1) PT3452039T (https=)
RS (1) RS66006B1 (https=)
SI (1) SI3452039T1 (https=)
SM (1) SMT202400389T1 (https=)
WO (1) WO2017192905A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113952460A (zh) * 2020-11-11 2022-01-21 长沙晶易医药科技有限公司 一种用于治疗斑秃的复方外用制剂及其制备方法

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2988629T3 (es) 2016-05-04 2024-11-21 Sun Pharmaceutical Ind Inc Tratamiento de trastornos de pérdida de cabello con inhibidores de JAK deuterados
AU2020219797B2 (en) * 2019-02-06 2025-10-16 Sun Pharmaceutical Industries, Inc. Process for preparing enantiomerically enriched jak inhibitors
WO2021236139A1 (en) 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Novel deuterated jak inhibitor and uses thereof
AU2021372512A1 (en) 2020-10-28 2023-06-22 Sun Pharmaceutical Industries, Inc. Regimens for the treatment of hair loss disorders with deuterated jak inhibitors
CN116916927A (zh) * 2020-10-28 2023-10-20 太阳医药工业公司 用于用氘化jak抑制剂治疗脱发症的方案
CA3228505A1 (en) 2021-08-11 2023-02-16 Sun Pharmaceutical Industries, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
WO2023018954A1 (en) 2021-08-12 2023-02-16 Concert Pharmaceuticals, Inc. Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors
CA3250876A1 (en) 2022-05-04 2023-11-09 Sun Pharmaceutical Industries, Inc. DOSAGE REGIMEN FOR TREATMENT WITH DEUTERATED JAK INHIBITORS
US12364699B2 (en) * 2023-10-10 2025-07-22 Sun Pharmaceuticals Industries, Inc. Method of treating hair loss disorders
US12247034B1 (en) 2024-04-19 2025-03-11 Sun Pharmaceutical Industries, Inc. Crystalline form of deuruxolitinib phosphate
WO2026020112A1 (en) * 2024-07-19 2026-01-22 Sun Pharmaceutical Industries, Inc. Oral formulations of deuruxolitinib
US20260027120A1 (en) * 2024-07-25 2026-01-29 Sun Pharmaceutical Industries, Inc. Methods of treatment of jak inhibition responsive conditions with deuterated jak inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103370076A (zh) * 2010-11-02 2013-10-23 纽约市哥伦比亚大学托管会 治疗毛发脱落疾病的方法
CN104507946A (zh) * 2012-07-30 2015-04-08 康塞特医药品有限公司 氘代依鲁替尼
CN104725380A (zh) * 2013-12-18 2015-06-24 康塞特医药品有限公司 卢索替尼的氘代衍生物
WO2015120110A2 (en) * 2014-02-07 2015-08-13 Auspex Pharmaceuticals, Inc. Novel pharmaceutical formulations
US20150239896A1 (en) * 2012-06-15 2015-08-27 Concert Pharmaceuticals, Inc. Deuterated Derivatives of Ruxolitinib

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
CN1255185C (zh) 2001-05-03 2006-05-10 弗·哈夫曼-拉罗切有限公司 无定形甲磺酸奈非那韦的药物剂型
MX2007003731A (es) 2004-09-29 2007-08-14 Johnson & Johnson Formas de dosis farmaceuticas de compuestos similares a rapamicina amorfos estables.
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
WO2007079139A2 (en) 2005-12-28 2007-07-12 Vertex Pharmaceuticals, Inc. Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
TWI720517B (zh) 2009-01-15 2021-03-01 美商英塞特公司 製造ｊａｋ抑制劑之方法及相關中間化合物
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
DK2830662T3 (da) 2012-03-29 2019-01-02 Univ Columbia Fremgangsmåder til behandlng af hårtabsforstyrrelser
PH12020551186B1 (en) 2012-11-15 2024-03-20 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
JP6367545B2 (ja) * 2013-12-17 2018-08-01 コンサート ファーマシューティカルズ インコーポレイテッド ルキソリチニブの重水素化誘導体
ES2988629T3 (es) * 2016-05-04 2024-11-21 Sun Pharmaceutical Ind Inc Tratamiento de trastornos de pérdida de cabello con inhibidores de JAK deuterados

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103370076A (zh) * 2010-11-02 2013-10-23 纽约市哥伦比亚大学托管会 治疗毛发脱落疾病的方法
US20150239896A1 (en) * 2012-06-15 2015-08-27 Concert Pharmaceuticals, Inc. Deuterated Derivatives of Ruxolitinib
CN104507946A (zh) * 2012-07-30 2015-04-08 康塞特医药品有限公司 氘代依鲁替尼
CN104725380A (zh) * 2013-12-18 2015-06-24 康塞特医药品有限公司 卢索替尼的氘代衍生物
WO2015120110A2 (en) * 2014-02-07 2015-08-13 Auspex Pharmaceuticals, Inc. Novel pharmaceutical formulations

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRITTANY G. CRAIGLOW ET AL: "Topical Ruxolitinib for the Treatment of Alopecia Universalis", 《JAMA DERMATOLOGY》 *
HARRIS ET AL: "Rapid Skin Repigmentation on Oral Ruxolitinib in a Patient with Coexistent Vitiligo and Alopecia Areata", 《JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY》 *
ROGER TUNG: "The Development of Deuterium-Containing Drugs", 《INNOVATIONS IN PHARMACEUTICAL TECHNOLOGY》 *
XING ET AL: "Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition", 《NATURE MEDICINE》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113952460A (zh) * 2020-11-11 2022-01-21 长沙晶易医药科技有限公司 一种用于治疗斑秃的复方外用制剂及其制备方法

Also Published As

Publication number Publication date
AU2017261286A1 (en) 2018-11-22
MX2023002321A (es) 2023-03-22
HUE068643T2 (hu) 2025-01-28
JP7586868B2 (ja) 2024-11-19
EP3452039A4 (en) 2019-12-25
US12076323B2 (en) 2024-09-03
PT3452039T (pt) 2024-10-07
US20190160068A1 (en) 2019-05-30
EP4424367A2 (en) 2024-09-04
US20240423986A1 (en) 2024-12-26
CN121868312A (zh) 2026-04-17
RS66006B1 (sr) 2024-10-31
KR20190003711A (ko) 2019-01-09
EP3452039A1 (en) 2019-03-13
JP7145080B2 (ja) 2022-09-30
MX2023002323A (es) 2023-03-22
PL3452039T3 (pl) 2024-11-18
KR20230086814A (ko) 2023-06-15
WO2017192905A1 (en) 2017-11-09
US10561659B2 (en) 2020-02-18
FI3452039T3 (fi) 2024-10-02
JP2019516684A (ja) 2019-06-20
CA3022519A1 (en) 2017-11-09
MX2021014175A (es) 2022-01-04
MX2023002324A (es) 2023-03-22
JP2025026895A (ja) 2025-02-26
MX2023002325A (es) 2023-03-22
KR102810262B1 (ko) 2025-05-19
US20200222408A1 (en) 2020-07-16
KR20250070139A (ko) 2025-05-20
ES2988629T3 (es) 2024-11-21
HRP20241345T1 (hr) 2024-12-20
SMT202400389T1 (it) 2024-11-15
MX2018013347A (es) 2019-09-02
JP2022171838A (ja) 2022-11-11
DK3452039T3 (da) 2024-10-07
MX388054B (es) 2025-03-19
BR112018072339A2 (pt) 2019-02-19
AU2023201112B2 (en) 2025-05-08
LT3452039T (lt) 2024-10-25
EP3452039B1 (en) 2024-07-03
SI3452039T1 (sl) 2024-12-31
EP4424367A3 (en) 2024-11-13
AU2025213576A1 (en) 2025-08-21
AU2017261286B2 (en) 2023-03-23
AU2023201112A1 (en) 2023-03-30

Similar Documents

Publication Publication Date Title
CN109069493A (zh) 用氘代jak抑制剂治疗脱毛障碍
TW201609100A (zh) 醫藥組合
JP2024531188A (ja) 重水素化ｊａｋ阻害剤による脱毛障害の治療
US20230390292A1 (en) Regimens for the treatment of hair loss disorders with deuterated jak inhibitors
HK40112813A (en) Treatment of hair loss disorders with deuterated jak inhibitors
HK40002100A (en) Treatment of hair loss disorders with deuterated jak inhibitors
CN119255806A (zh) 用于用氘化jak抑制剂进行治疗的剂量方案
EA052710B1 (ru) Лечение нарушений, характеризующихся выпадением волос, с помощью дейтерированных ингибиторов jak
OA21444A (en) Regimens For The Treatment Of Hair Loss Disorders With Deuterated Jak Inhibitors.
CN116916927A (zh) 用于用氘化jak抑制剂治疗脱发症的方案

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40002100

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20231011

Address after: new jersey

Applicant after: Sun Pharmaceutical Industry Co.,Ltd.

Address before: Massachusetts

Applicant before: Concert Pharmaceuticals, Inc.